

Adamas Pharmaceuticals Inc
 Form 4
 July 09, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 MDV IX LP

2. Issuer Name and Ticker or Trading Symbol
 Adamas Pharmaceuticals Inc
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 07/07/2015

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

C/O MOHR DAVIDOW
 VENTURES, 3000 SAND HILL
 ROAD, SUITE 3-290

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

MENLO PARK, CA 94025

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) | | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|---------|---|--|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 07/07/2015 | | S ⁽¹⁾ | | 25,737 | D | \$ 27.5452 <u>(2)</u> | 299,749 | I | MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. ⁽³⁾ |
| Common Stock | 07/08/2015 | | S ⁽¹⁾ | | 3,100 | D | \$ 27.551 <u>(4)</u> | 296,649 | I | MDV IX, L.P., as |

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

| | | | | | | | |
|--------------|--|--|--|--|-----------|---|---|
| Common Stock | | | | | 3,772,686 | I | nominee for MDV IX, L.P., and MDV ENF IX, L.P. ⁽³⁾ |
| Common Stock | | | | | 265,150 | I | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP ⁽⁵⁾ |
| Common Stock | | | | | 6,043 | I | MDV VII, L.P. ⁽⁵⁾ |
| Common Stock | | | | | 3,146 | I | MDV ENF VII (A), L.P. ⁽⁵⁾ |
| Common Stock | | | | | 25,661 | I | MDV ENF VII (B), L.P. ⁽⁵⁾ |
| Common Stock | | | | | | | MDV VII Leaders' Fund, L.P. ⁽⁵⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene |
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|------------------------|
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|------------------------|

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

| Derivative Security | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | (Instr. 3 and 4) |
|---------------------|---|------|---|-----|-----|------------------|-----------------|-------|----------------------------|------------------|
| | | | | | | | | | | Owned |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| MDV IX LP C/O MOHR DAVIDOW VENTURES 3000 SAND HILL ROAD, SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| Seventh MDV Partners, L.L.C. 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| Ninth MDV Partners, L.L.C. 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| FEIBER JONATHAN D 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| SCHOENDORF NANCY J 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| MDV ENF VII (A), L.P. 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| MDV ENF VII (B), L.P. 3000 SAND HILL ROAD SUITE 3-290 MENLO PARK, CA 94025 | | X | | |
| MDV VII Leaders' Fund, L.P. 3000 SAND HILL ROAD | | X | | |

SUITE 3-290
MENLO PARK, CA 94025

MDV VII LP
C/O MOHR DAVIDOW VENTURES
3000 SAND HILL ROAD, SUITE 3-290
MENLO PARK, CA 94025

X

Signatures

Brett A. Teele

07/09/2015

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by MDV IX on December 15, 2014.

Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was \$27.50 and \$27.84 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

(3) Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.

(4) Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was \$27.50 and \$27.72 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

(5) Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.